We also found that disease type ( de novo or secondary) showed a slight trend in relation to CR rates, although the relationship was not significant.
← all excerpts
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
1
—
—